Johnson & Johnson slips as weak device sales cloud earnings beat
JNJ•Johnson & Johnson shares fell 4.4% after third-quarter MedTech sales rose 2.5% to $8.6 billion, below estimates, despite adjusted earnings per share of $2.59 and sales of $25.4 billion beating forecasts. The company raised its 2026 forecast to about $101.2 billion in reported sales and adjusted EPS of $11.10 at the midpoint.
1. MedTech sales miss
Third-quarter MedTech sales rose 2.5% to $8.6 billion, missing analysts’ estimate of $8.71 billion. Adjusted EPS of $2.59 beat the $2.54 estimate, while sales of $25.4 billion exceeded the $25.28 billion estimate. Shares fell 4.4% to $252.38.
2. Forecast raised
Johnson & Johnson now expects about $101.2 billion in 2026 reported sales and adjusted EPS of $11.10 at the midpoint, up from prior forecasts of about $101.1 billion and $11.04. Analysts on average expect 2026 sales of about $101.3 billion and adjusted EPS of $11.08.
